Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]
MicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorpora...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2013-08-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/2-136/v2 |
id |
doaj-20cfbdf44e594b2e82342cac93c3ff5b |
---|---|
record_format |
Article |
spelling |
doaj-20cfbdf44e594b2e82342cac93c3ff5b2020-11-25T03:12:08ZengF1000 Research LtdF1000Research2046-14022013-08-01210.12688/f1000research.2-136.v22163Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3]Per Hydbring0Gayane Badalian-Very1Department of Genetics and Medicine, Harvard Medical School, Boston MA, 02115, USADepartment of Medicine, Brigham and Women's Hospital, Boston MA, 02115, USAMicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorporated into the RNA Induced Silencing Complex from where it silences up to hundreds of mRNA transcript by inducing mRNA degradation or blocking protein translation. Apart from involvement in a variety of biological processes, microRNAs were early recognized for their potential in disease diagnostics and therapeutics. Due to their stability, microRNAs could be used as biomarkers. Currently, there are microRNA panels helping physicians determining the origins of cancer in disseminated tumors. The development of microRNA therapeutics has proved more challenging mainly due to delivery issues. However, one drug is already in clinical trials and several more await entering clinical phases. This review summarizes what has been recognized pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights individual microRNA drugs in running platforms driven by four leading microRNA-therapeutic companies.http://f1000research.com/articles/2-136/v2Cancer TherapeuticsMedical Genetics |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Per Hydbring Gayane Badalian-Very |
spellingShingle |
Per Hydbring Gayane Badalian-Very Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] F1000Research Cancer Therapeutics Medical Genetics |
author_facet |
Per Hydbring Gayane Badalian-Very |
author_sort |
Per Hydbring |
title |
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] |
title_short |
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] |
title_full |
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] |
title_fullStr |
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] |
title_full_unstemmed |
Clinical applications of microRNAs [v2; ref status: indexed, http://f1000r.es/1o3] |
title_sort |
clinical applications of micrornas [v2; ref status: indexed, http://f1000r.es/1o3] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2013-08-01 |
description |
MicroRNAs represent a class of small RNAs derived from polymerase II controlled transcriptional regions. The primary transcript forms one or several bulging double stranded hairpins which are processed by Drosha and Dicer into hetero-duplexes. The targeting microRNA strand of the duplex is incorporated into the RNA Induced Silencing Complex from where it silences up to hundreds of mRNA transcript by inducing mRNA degradation or blocking protein translation. Apart from involvement in a variety of biological processes, microRNAs were early recognized for their potential in disease diagnostics and therapeutics. Due to their stability, microRNAs could be used as biomarkers. Currently, there are microRNA panels helping physicians determining the origins of cancer in disseminated tumors. The development of microRNA therapeutics has proved more challenging mainly due to delivery issues. However, one drug is already in clinical trials and several more await entering clinical phases. This review summarizes what has been recognized pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights individual microRNA drugs in running platforms driven by four leading microRNA-therapeutic companies. |
topic |
Cancer Therapeutics Medical Genetics |
url |
http://f1000research.com/articles/2-136/v2 |
work_keys_str_mv |
AT perhydbring clinicalapplicationsofmicrornasv2refstatusindexedhttpf1000res1o3 AT gayanebadalianvery clinicalapplicationsofmicrornasv2refstatusindexedhttpf1000res1o3 |
_version_ |
1724651317622734848 |